Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Rapid and convenient assays to assess potential inhibitory activity on in vitro hepatitis A replication.

Debing Y, Kaplan GG, Neyts J, Jochmans D.

Antiviral Res. 2013 May;98(2):325-31. doi: 10.1016/j.antiviral.2013.03.016. Epub 2013 Mar 23.

PMID:
23528258
2.

The JAK2 inhibitor AZD1480 inhibits hepatitis A virus replication in Huh7 cells.

Jiang X, Kanda T, Nakamoto S, Saito K, Nakamura M, Wu S, Haga Y, Sasaki R, Sakamoto N, Shirasawa H, Okamoto H, Yokosuka O.

Biochem Biophys Res Commun. 2015 Mar 20;458(4):908-12. doi: 10.1016/j.bbrc.2015.02.058. Epub 2015 Feb 19.

PMID:
25704089
3.

Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha.

Yang L, Kiyohara T, Kanda T, Imazeki F, Fujiwara K, Gauss-Müller V, Ishii K, Wakita T, Yokosuka O.

Virol J. 2010 Sep 3;7:212. doi: 10.1186/1743-422X-7-212.

4.

Novel perspectives for hepatitis A virus therapy revealed by comparative analysis of hepatitis C virus and hepatitis A virus RNA replication.

Esser-Nobis K, Harak C, Schult P, Kusov Y, Lohmann V.

Hepatology. 2015 Aug;62(2):397-408. doi: 10.1002/hep.27847. Epub 2015 May 20.

PMID:
25866017
5.

Hepatitis A virus inhibits cellular antiviral defense mechanisms induced by double-stranded RNA.

Brack K, Berk I, Magulski T, Lederer J, Dotzauer A, Vallbracht A.

J Virol. 2002 Dec;76(23):11920-30.

6.

Molecular biology and inhibitors of hepatitis A virus.

Debing Y, Neyts J, Thibaut HJ.

Med Res Rev. 2014 Sep;34(5):895-917. doi: 10.1002/med.21292. Epub 2013 May 30. Review.

PMID:
23722879
7.

The sirtuin inhibitor sirtinol inhibits hepatitis A virus (HAV) replication by inhibiting HAV internal ribosomal entry site activity.

Kanda T, Sasaki R, Nakamoto S, Haga Y, Nakamura M, Shirasawa H, Okamoto H, Yokosuka O.

Biochem Biophys Res Commun. 2015 Oct 23;466(3):567-71. doi: 10.1016/j.bbrc.2015.09.083. Epub 2015 Sep 24.

PMID:
26388050
8.

Interleukin-29 suppresses hepatitis A and C viral internal ribosomal entry site-mediated translation.

Kanda T, Wu S, Kiyohara T, Nakamoto S, Jiang X, Miyamura T, Imazeki F, Ishii K, Wakita T, Yokosuka O.

Viral Immunol. 2012 Oct;25(5):379-86. doi: 10.1089/vim.2012.0021.

PMID:
23035851
9.

Anti-HAV activity of some newly synthesized triazolo[4,3-b]pyridazines.

Shamroukh AH, Ali MA.

Arch Pharm (Weinheim). 2008 Apr;341(4):223-30. doi: 10.1002/ardp.200700181.

PMID:
18214848
10.

Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid.

Hung HC, Chen TC, Fang MY, Yen KJ, Shih SR, Hsu JT, Tseng CP.

J Antimicrob Chemother. 2010 Apr;65(4):676-83. doi: 10.1093/jac/dkp502. Epub 2010 Jan 20.

PMID:
20089540
11.

Interference of hepatitis A virus replication by small interfering RNAs.

Kanda T, Kusov Y, Yokosuka O, Gauss-Müller V.

Biochem Biophys Res Commun. 2004 May 28;318(2):341-5.

PMID:
15120607
13.

Suppression of hepatitis A virus genome translation and replication by siRNAs targeting the internal ribosomal entry site.

Kanda T, Zhang B, Kusov Y, Yokosuka O, Gauss-Müller V.

Biochem Biophys Res Commun. 2005 May 20;330(4):1217-23.

PMID:
15823573
14.

Influence of twenty potentially antiviral substances on in vitro multiplication of hepatitis A virus.

Widell A, Hansson BG, Oberg B, Nordenfelt E.

Antiviral Res. 1986 Mar;6(2):103-12.

PMID:
3010855
15.

Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity.

Arita M, Kojima H, Nagano T, Okabe T, Wakita T, Shimizu H.

J Virol. 2011 Mar;85(5):2364-72. doi: 10.1128/JVI.02249-10. Epub 2010 Dec 22.

16.

Identification of BPR3P0128 as an inhibitor of cap-snatching activities of influenza virus.

Hsu JT, Yeh JY, Lin TJ, Li ML, Wu MS, Hsieh CF, Chou YC, Tang WF, Lau KS, Hung HC, Fang MY, Ko S, Hsieh HP, Horng JT.

Antimicrob Agents Chemother. 2012 Feb;56(2):647-57. doi: 10.1128/AAC.00125-11. Epub 2011 Sep 19.

18.

Methisoprinol-effect on the replication cycle of human hepatitis A virus.

Divizia M, Venuti A, Degener AM, Perez-Bercoff R, Panà A.

Microbiologica. 1992 Oct;15(4):323-8.

PMID:
1279362
19.

In vitro surrogate models to aid in the development of antivirals for the containment of foot-and-mouth disease outbreaks.

Osiceanu AM, Murao LE, Kollanur D, Swinnen J, De Vleeschauwer AR, Lefebvre DJ, De Clercq K, Neyts J, Goris N.

Antiviral Res. 2014 May;105:59-63. doi: 10.1016/j.antiviral.2014.02.009. Epub 2014 Feb 25.

PMID:
24583031
20.

The cytopathic 18f strain of Hepatitis A virus induces RNA degradation in FrhK4 cells.

Kulka M, Chen A, Ngo D, Bhattacharya SS, Cebula TA, Goswami BB.

Arch Virol. 2003 Jul;148(7):1275-300.

PMID:
12827461

Supplemental Content

Support Center